Clinical Trial Details

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients with Traumatic Brain Injury (TBI) Protocol NO: Neu-2566-TBI-001
Study Purpose
The purpose of this study is primarily to assess the safety of the new investigational drug, NNZ-2566, in human subjects with TBI. . An additional purpose of the study is to find out if NNZ-2566 improves abnormal brain electrical activity and reduces or prevents brain seizures in the acute stage of TBI.
Study Plan
Intravenous Infusion of the study drug or Placebo: . Neither you nor the study doctors will know which experimental medication you received until the study is completed.

Principal Investigator
Andrew J. Kerwin, M.D., FACS

Sub Investigator
Indermeet S. Bhullar, M.D.

Sub Investigator
J. B. Burns Jr., D.O., M.S.

Sub Investigator
Christopher Y. Hopkins, M.D.
Emergency Medicine

Sub Investigator
Jin H. Ra, M.D.

Sub Investigator
Joseph J. Tepas III, M.D.

News & Announcements

Patients experience “a whole new world” after weight loss surgery


Imagine waiting in line for hours to take your kids on a theme park ride, only to be kicked off because you’re too heavy. Imagin... [full story]

UF Health hospitals recognized among nation’s best


UF Health Jacksonville has been recognized as one of the best hospitals in North Florida, based on U.S. News & World Report’s... [full story]

Nine College of Medicine – Jacksonville faculty members promoted


Nine faculty members at the University of Florida College of Medicine – Jacksonville have received promotions that will take effe... [full story]

Upcoming Events

Nov 19